Vertex Value Stock - Dividend - Research Selection
Vertex Pharmaceuticals
ISIN: US92532F1003, WKN: 882807
Market price: 254,17 USD
Vertex Pharmaceuticals Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 10-02-2022 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 2.643.500.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -235.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | 2.408.499.968 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 10.100.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 13.432.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | 2.342.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | 9,018 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 259.707.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 7.574.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | VRTX |
| Market Capitalization | 66.009.726.976,00 USD |
| Country | United States |
| Indices | MSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500 |
| Sectors | Biotechnology |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | 2000-08-24,2.0000/1.0000 |
| Internet | www.vrtx.com |
Description of the company
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company's two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.